Evidence map›Paper›PMID 24690681›Full record

ArticlePloS one2014

Suppression by thimerosal of ex-vivo CD4+ T cell response to influenza vaccine and induction of apoptosis in primary memory T cells.

Emily Loison, Béatrice Poirier-Beaudouin, Valérie Seffer, Audrey Paoletti, Vered Abitbol, Eric Tartour, Odile Launay, Marie-Lise Gougeon

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01022749 (Prospective, Multicentre, Open-label Study Evaluating the Immunogenicity and Safety of Influenza Vaccine in Patients With Inflammatory Bowel Disease), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01022749 phase3completednot on this map

Prospective, Multicentre, Open-label Study Evaluating the Immunogenicity and Safety of Influenza Vaccine in Patients With Inflammatory Bowel Disease (IBD) Receiving or Not Immunosuppressive Therapy

TypeinterventionalSponsorAssistance Publique - Hôpitaux de ParisRan2009 to 2013Enrolled228ConditionsInflammatory Bowel Disease (IBD)ArmsVaccine, Vaccine anti-H1N1
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Emily LoisonAntiviral Immunity Biotherapy and Vaccine Unit, Institut Pasteur, Paris, France.
Béatrice Poirier-BeaudouinAntiviral Immunity Biotherapy and Vaccine Unit, Institut Pasteur, Paris, France.
Valérie SefferAntiviral Immunity Biotherapy and Vaccine Unit, Institut Pasteur, Paris, France.
Audrey PaolettiInserm U1030, Institut Gustave Roussy, Villejuif, France.
Vered AbitbolGastroenterology Department, Hôpital Cochin, AP-HP, Paris, France.
Eric TartourInserm U970, Université Paris Descartes, PARCC/HEGP, Paris, France.
Odile LaunayCentre d'Investigation Clinique BT-505, Hôpital Cochin, AP-HP, Paris, France.
Marie-Lise GougeonAntiviral Immunity Biotherapy and Vaccine Unit, Institut Pasteur, Paris, France.
Institut Pasteur · FRAssistance Publique – Hôpitaux de Paris · FRInserm · FRUniversité Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thimerosal is a preservative used widely in vaccine formulations to prevent bacterial and fungal contamination in multidose vials of vaccine. Thimerosal was included in the multidose non-adjuvanted pandemic 2009 H1N1 vaccine Panenza. In the context of the analysis of the ex-vivo T cell responses directed against influenza vaccine, we discovered the in vitro toxicity Panenza, due to its content in thimerosal. Because thimerosal may skew the immune response to vaccines, we investigated in detail the ex-vivo effects of thimerosal on the fate and functions of T cells in response to TCR ligation. We report that ex-vivo exposure of quiescent or TCR-activated primary human T cells to thimerosal induced a dose-dependent apoptotic cell death associated with depolarization of mitochondrial membrane, generation of reactive oxygen species, cytochrome c release from the mitochondria and caspase-3 activation. Moreover, exposure to non-toxic concentrations of thimerosal induced cell cycle arrest in G0/G1 phase of TCR-activated T cells, and inhibition of the release of proinflammatory cytokines such as IFN gamma, IL-1 beta, TNF alpha, IL-2, as well as the chemokine MCP1. No shift towards Th2 or Th17 cells was detected. Overall these results underline the proapoptotic effect of thimerosal on primary human lymphocytes at concentrations 100 times less to those contained in the multidose vaccine, and they reveal the inhibitory effect of this preservative on T-cell proliferation and functions at nanomolar concentrations.

Indexed as

AdultApoptosisCaspase 3CD4-Positive T-LymphocytesCell Cycle CheckpointsCell ProliferationCells, CulturedChemokinesCytochromes cDose-Response Relationship, ImmunologicEnzyme ActivationHumansImmunologic MemoryInfluenza A Virus, H1N1 SubtypeInfluenza VaccinesLymphocyte ActivationCaspase 3ChemokinesCytochromes cInfluenza VaccinesMitochondrial Membrane Transport ProteinsMitochondrial Permeability Transition Porepanenza vaccineReactive Oxygen SpeciesReceptors, Antigen, T-CellThimerosal

Identifiers

PMID24690681
PMCPMC3972181
OpenAlexW2047777384

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.